NEUE 19-NORGESTAGENE IN DER HRT: DAS ENDE DER GESTAGENDISKUSSION?

E. Merkle
In: Journal für Menopause · 2001 · vol. 8(1) , pp. 2–11 · W340288796
article OA: closed CC0 Metadata only
View on OpenAlex
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

New 19-norprogestins like dienogest and nomegestrol acetate aim to combine favorable metabolic profiles with effective endometrial effects, and their differing impacts should not be dismissed as therapeutically insignificant.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Summary: New 19-norprogestins such as the estrane derivative dienogest or the 19-norprogesterone derivatives nomegestrol acetate, trimegestone and promegestone have been developed with the aim of combining the potentially advantageous metabolic characteristics of 17α-hydroxyprogesterone derivatives with the very effective endometrium effect of conventional 19-nortestosterone derivatives. Even if the clinical relevance of the differing effects of the various gestagens on individual surrogate parameters may be disputed, one must not draw the conclusion that these differences have no therapeutic significance whatsoever. This would not do justice to the claims

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (3)

References (57)

Source provenance

openalex
last seen: 2026-05-10T10:02:44.146860+00:00
License: CC0 · commercial use OK